Abstract
We retrospectively assessed the clinical uses and results of sildenafil in the treatment of erectile dysfunction (ED) in daily clinical practice from a cohort of 1658 subjects at a multispeciality medical center from 1999 to 2001 through a chart review, mailed questionnaire and telephone interview. The overall follow-up rate was 77.8% (1290/1658). The mean age was 63.8 y and ED duration was 3.4 y, and 44.6% of them had one or more concomitant conditions. The mean score of the International Index of Erectile Function erectile function domain was 12.7 in 314 nonselective subjects, and 75% of them had moderate to severe ED. The average number of purchase-visits and tablets of sildenafil purchased was 2.27 and 10.8 per person, respectively, and the prescription refill rate was 58.6%. Urology accounts for 91.4% of the specialties of prescribers. The response rate was 72.0%, which was significantly lower in subjects with diabetes, ischemic heart disease and following radical pelvic surgery than those without. Subjects with psychogenic etiology had the highest response rate, while those following radical pelvic surgery the lowest. Of the nonresponders, 67% did not try the maximum dose of 100 mg and 71.1% bought no more than four tablets. Adverse events were reported in 20.1% of the subjects. No one discontinued the treatment because of the adverse events. Mortality occurred in 17 subjects and none was considered related to sildenafil use. In conclusion, sildenafil was effective and safe in the treatment of ED in clinical practice. Compared with clinical trials or prospective clinical practice based studies, lack of dose titration, less follow-up visits and inadequate attempts before giving up were the main shortfalls in daily practice.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 8 print issues and online access
$259.00 per year
only $32.38 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Boolell M et al. Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. Int J Impot Res 1996; 8: 47–52.
Goldstein I et al. Oral sildenafil in the treatment of erectile dysfunction. N Engl J Med 1998; 338: 1397–1404.
McCullough AR et al. Achieving treatment optimization with sildenafil citrate (Viagra®) in patients with erectile dysfunction. Urology 2002; 60 (Suppl 2B): 28–38.
Rosen RC et al. The International Index of Erectile Dysfunction (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 1997; 49: 822–830.
Gil A . Erectile dysfunction in a primary care setting: results of an observational, no-control-group, prospective study with sildenafil under routine conditions of use. Int J Impot Res 2001; 13: 338–347.
Guay AT et al. Efficacy and safety of sildenafil citrate for treatment of erectile dysfunction in a population with associated organic factors. J Androl 2001; 22: 793–797.
Palumbo F et al. Sildenafil: efficacy and safety in daily clinical experience. Eur Urol 2001; 40: 176–180.
Marks LS et al. Treatment of erectile dysfunction with sildenafil. Urology 1999; 53: 19–24.
McMahon CG, Samali R, Johnson H . Efficacy, safety and patient acceptance of sildenafil citrate as treatment for erectile dysfunction. J Urol 2000; 164: 1192–1196.
Jarow JP, Burnett AL, Geringer AM . Clinical efficacy of sildenafil citrate based on etiology and response to prior treatment. J Urol 1999; 162: 722–725.
Martinez-Jabaloyas JM et al. Prognostic factors for response to sildenafil in patients with erectile dysfunction. Eur Urol 2001; 40: 641–647.
Padma-Nathan H et al. Efficacy and safety of oral sildenafil in the treatment of erectile dysfunction: a double-blind, placebo-controlled study of 329 patients. Int J Clic Pract 1998; 52: 375–380.
Chen KK et al. ASSESS-3: a randomized, double-blind, flexible-dose clinical trial of the efficacy and safety of oral sildenafil in the treatment of men with erectile dysfunction. Int J Impot Res 2001; 13: 221–229.
Wyllie MG . The phosphodiesterase inhibitor ‘war’. BJU Int 2003; 91: 573–574.
Morales A et al. Clinical safety of oral sildenafil citrate (Viagra™) in the treatment of erectile dysfunction. Int J Impot Res 1998; 10: 69–74.
Wallis RM et al. Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in vitro. Am J Cardiol 1999; 83 (Suppl 5A): 3C–12C.
Padma-Nathan H et al. A 4-year update on the safety of sildenafil citrate (Viagra™). Urology 2002; 60 (Suppl 2B): 67–90.
Moreira SG et al. Side-effect profile of sildenafil citrate (Viagra) in clinical practice. Urology 2000; 56: 474–476.
Huang ST . Use of sildenafil citrate in treatment of Taiwanese men with erectile dysfunction: a single center experience. Chang Gung Med J 2001; 24: 91–96.
DeBusk R et al. Management of sexual dysfunction in patients with cardiovascular disease: recommendations of the Princeton Consensus Panel. Am J Cardiol 2000; 86: 175–181.
Ishikura F et al. Effects of sildenafil citrate (Viagra) combined with nitrate on the heart. Circulation 2000; 102: 2516–2521.
Wysowski DK, Swann J . Use of medications for erectile dysfunction in the United States, 1996 through 2001. J Urol 2003; 169: 1040–1042.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Jiann, BP., Yu, CC., Tsai, JY. et al. What to learn about sildenafil in the treatment of erectile dysfunction from 3-year clinical experience. Int J Impot Res 15, 412–417 (2003). https://doi.org/10.1038/sj.ijir.3901047
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.ijir.3901047
Keywords
This article is cited by
-
Assessing satisfaction in men and their female partners after treatment with phosphodiesterase type 5 inhibitors for erectile dysfunction
International Journal of Impotence Research (2013)
-
Hardness, function, emotional well-being, satisfaction and the overall sexual experience in men using 100-mg fixed-dose or flexible-dose sildenafil citrate
International Journal of Impotence Research (2010)
-
Sildenafil citrate (Viagra) treatment for erectile dysfunction: an updated profile of response and effectiveness
International Journal of Impotence Research (2006)
-
Compliance of sildenafil treatment for erectile dysfunction and factors affecting it
International Journal of Impotence Research (2006)
-
Impact of introduction of sildenafil on other treatment modalities for erectile dysfunction: a study of nationwide and local hospital sales
International Journal of Impotence Research (2004)